glp-1 agonist consultation process and Anesthesia: Considerations and Cautions for CRNAs Perioperative Use of GLP-1 Receptor
Description
While U.S
Pooled results from four RCTs ( 2 = 83%) and FPG levels (MD: -31.44, 95% CI: -39.76, -23.13
[DOI] [PMC free article] [PubMed] [Google Scholar] 66
March 2024 : The US FDA approved a label expansion for WEGOVY based on a supplemental New Drug Application (sNDA) for the indication of reducing risks of major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal heart attack (myocardial infarction), or non-fatal stroke in adults with either overweight or obesity and established CVD
PKA enhances the acute insulin response leading to the restoration of glucose control
